Anne-Marie Martinez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anne-Marie Martinez has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Giacomo Cavalli
IGH, UMR9002, Univ Montpellier, CNRS, INSERM , 141 Rue de la Cardonille, Montpellier Cedex 5 34396
18 shared publications - Bernd Schuettengruber
IGH, UMR9002, Univ Montpellier, CNRS, INSERM , 141 Rue de la Cardonille, Montpellier Cedex 5 34396
6 shared publications Vincent Loubiere
IGH, UMR9002, Univ Montpellier, CNRS, INSERM , 141 Rue de la Cardonille, Montpellier Cedex 5 34396
6 shared publicationsAnna Delest
2 shared publicationsB. Győrffy
Semmelweis University Department of Bioinformatics, Budapest, Hungary
2 shared publicationsB. Schuettengruber
Institute of Human Genetics, CNRS, University of Montpellier, Montpellier, France
2 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Oxford University Press (OUP) in Genetics
A comprehensive HA-tagged PRC1 toolkit enables standardized chromatin profiling and proteomic analysis in Drosophila melanogaster
Polycomb group (PcG) proteins are evolutionarily conserved epigenetic regulators that maintain transcriptional states during development and are frequently dysregulated in disease. Here, we generated a comprehensive collection of endogenously HA-tagged alleles for the core components of Polycomb repressive complex 1 (PRC1) and additional chromatin regulators in Drosophila melanogaster using CRISPR/Cas9-mediated genome engineering. We show that endogenous HA tagging preserves protein expression, chromatin localization, and genome-wide binding profiles, enabling direct comparison using a common antibody to analyze distinct PcG subunits. Proteomic analyses recovered known components of canonical and non-canonical PRC1 and Polycomb repressive complex 2 complexes and identified additional PcG-associated factors. Notably, multiple components of the nuclear pore complex (NPC) were detected as PcG interactors, and genetic analyses confirmed a functional interaction between them. This resource provides a platform for standardized analysis of Polycomb function and chromatin regulation that can easily be extended to other chromatin regulatory complexes and applied across different developmental stages.
- 22 October 2026
- Published by Oxford University Press (OUP) in Genetics
Open AccessA comprehensive HA-tagged PRC1 toolkit enables standardized chromatin profiling and proteomic analysis in Drosophila melanogaster
Polycomb group (PcG) proteins are evolutionarily conserved epigenetic regulators that maintain transcriptional states during development and are frequently dysregulated in disease. Here, we generated a comprehensive collection of endogenously HA-tagged alleles for the core components of Polycomb repressive complex 1 (PRC1) and additional chromatin regulators in Drosophila melanogaster using CRISPR/Cas9-mediated genome engineering. We show that endogenous HA tagging preserves protein expression, chromatin localization, and genome-wide binding profiles, enabling direct comparison using a common antibody to analyze distinct PcG subunits. Proteomic analyses recovered known components of canonical and non-canonical PRC1 and Polycomb repressive complex 2 complexes and identified additional PcG-associated factors. Notably, multiple components of the nuclear pore complex (NPC) were detected as PcG interactors, and genetic analyses confirmed a functional interaction between them. This resource provides a platform for standardized analysis of Polycomb function and chromatin regulation that can easily be extended to other chromatin regulatory complexes and applied across different developmental stages.
- Open Access
A comprehensive HA-tagged PRC1 toolkit enables standardized chromatin profiling and proteomic analysis in Drosophila melanogaster
Polycomb group (PcG) proteins are evolutionarily conserved epigenetic regulators that maintain transcriptional states during development and are frequently misregulated in disease. Here, we generated a comprehensive collection of endogenously HA-tagged alleles for the core components of Polycomb Repressive Complex 1 (PRC1) and additional chromatin regulators in Drosophila melanogaster using CRISPR/Cas9-mediated genome engineering. We show that endogenous HA tagging preserves protein expression, chromatin localization, and genome-wide binding profiles, enabling direct comparison using a common antibody to analyze distinct PcG subunits. Proteomic analyses recovered known components of canonical and non-canonical PRC1 and PRC2 complexes and identified additional PcG-associated factors. Notably, multiple components of the nuclear pore complex (NPC) were detected as PcG interactors, and genetic analyses confirmed a functional interaction between them. This resource provides a platform for standardized analysis of Polycomb function and chromatin regulation that can easily be extended to other chromatin regulatory complexes and applied across different developmental stages
Open AccessA comprehensive HA-tagged PRC1 toolkit enables standardized chromatin profiling and proteomic analysis in Drosophila melanogaster
Polycomb group (PcG) proteins are evolutionarily conserved epigenetic regulators that maintain transcriptional states during development and are frequently misregulated in disease. Here, we generated a comprehensive collection of endogenously HA-tagged alleles for the core components of Polycomb Repressive Complex 1 (PRC1) and additional chromatin regulators in Drosophila melanogaster using CRISPR/Cas9-mediated genome engineering. We show that endogenous HA tagging preserves protein expression, chromatin localization, and genome-wide binding profiles, enabling direct comparison using a common antibody to analyze distinct PcG subunits. Proteomic analyses recovered known components of canonical and non-canonical PRC1 and PRC2 complexes and identified additional PcG-associated factors. Notably, multiple components of the nuclear pore complex (NPC) were detected as PcG interactors, and genetic analyses confirmed a functional interaction between them. This resource provides a platform for standardized analysis of Polycomb function and chromatin regulation that can easily be extended to other chromatin regulatory complexes and applied across different developmental stages
- 1 August 2025
- Published by Springer Nature
- Vol. 1482, 155-179
Epigenetic Regulation in Drosophila Tumor Models
This chapter investigates the role of epigenetic regulation in tumorigenesis using Drosophila melanogaster as a model organism. It underscores the advantages of Drosophila for studying epigenetic mechanisms in cancer and focuses on key epigenetic regulators, such as Polycomb and Trithorax complexes, which modulate chromatin structure and gene expression. The chapter explores the roles of these complexes in various Drosophila tissues, including imaginal discs, the central nervous system, and adult stem cells, emphasizing their context-dependent functions in both tumor suppression and promotion. It challenges the somatic mutation theory (SMT) of cancer by emphasizing theories and experimental results suggesting a major contribution of epigenetic mechanisms in cancer initiation and progression. The concept of tumor reversion through epigenetic reprogramming is introduced, suggesting that non-mutational changes can revert tumor cells to a benign state. The tissue organization field theory (TOFT) and the epigenetic progenitor hypothesis are discussed to explain the epigenetic origins of cancer. Significant data highlight the critical role of epigenetic regulation in maintaining cellular identity, preventing tumorigenesis, and contributing to cancer when dysregulated. The chapter discusses the potential for epigenetic therapies and the need for further research to unravel the complex interplay between genetic and epigenetic factors in cancer.
- 1 August 2025
- Published by Springer Nature
- Vol. 1482, 155-179
Epigenetic Regulation in Drosophila Tumor Models
This chapter investigates the role of epigenetic regulation in tumorigenesis using Drosophila melanogaster as a model organism. It underscores the advantages of Drosophila for studying epigenetic mechanisms in cancer and focuses on key epigenetic regulators, such as Polycomb and Trithorax complexes, which modulate chromatin structure and gene expression. The chapter explores the roles of these complexes in various Drosophila tissues, including imaginal discs, the central nervous system, and adult stem cells, emphasizing their context-dependent functions in both tumor suppression and promotion. It challenges the somatic mutation theory (SMT) of cancer by emphasizing theories and experimental results suggesting a major contribution of epigenetic mechanisms in cancer initiation and progression. The concept of tumor reversion through epigenetic reprogramming is introduced, suggesting that non-mutational changes can revert tumor cells to a benign state. The tissue organization field theory (TOFT) and the epigenetic progenitor hypothesis are discussed to explain the epigenetic origins of cancer. Significant data highlight the critical role of epigenetic regulation in maintaining cellular identity, preventing tumorigenesis, and contributing to cancer when dysregulated. The chapter discusses the potential for epigenetic therapies and the need for further research to unravel the complex interplay between genetic and epigenetic factors in cancer.
- Open Access
- 25 February 2025
- Published by MathDoc/Centre Mersenne in Comptes Rendus. Biologies
- Vol. 348 (G1) , 43-53
A possible role for epigenetics in cancer initiation
Cancer is one of the leading causes of mortality worldwide. Known since antiquity, its understanding has evolved over time and has significantly advanced with new technologies over the past four decades. Cancer initiation is currently admitted to be explainable by the somatic mutation theory, which postulates that DNA mutations altering the function of oncogenes and tumor suppressor genes initiate cancer. In addition to these mutations, epigenetic alterations, which heritably change gene expression without altering the DNA sequence, also play a key role. Recent data suggests that epigenetic components regulate all aspects of tumor progression, including cancer initiation. These discoveries prompt a reevaluation of the somatic mutation theory, of cancer prevention and treatment strategies.
- 25 February 2025
- Published by MathDoc/Centre Mersenne in Comptes Rendus. Biologies
- Vol. 348 (G1) , 43-53
Open AccessA possible role for epigenetics in cancer initiation
Cancer is one of the leading causes of mortality worldwide. Known since antiquity, its understanding has evolved over time and has significantly advanced with new technologies over the past four decades. Cancer initiation is currently admitted to be explainable by the somatic mutation theory, which postulates that DNA mutations altering the function of oncogenes and tumor suppressor genes initiate cancer. In addition to these mutations, epigenetic alterations, which heritably change gene expression without altering the DNA sequence, also play a key role. Recent data suggests that epigenetic components regulate all aspects of tumor progression, including cancer initiation. These discoveries prompt a reevaluation of the somatic mutation theory, of cancer prevention and treatment strategies.
- Open Access
- 18 June 2024
- Published by Springer Nature in Histochemistry and Cell Biology
- Vol. 162 (1-2) , 133-147
Sustained inactivation of the Polycomb PRC1 complex induces DNA repair defects and genomic instability in epigenetic tumors
Cancer initiation and progression are typically associated with the accumulation of driver mutations and genomic instability. However, recent studies demonstrated that cancer can also be driven purely by epigenetic alterations, without driver mutations. Specifically, a 24-h transient downregulation of polyhomeotic (ph-KD), a core component of the Polycomb complex PRC1, is sufficient to induce epigenetically initiated cancers (EICs) in Drosophila, which are proficient in DNA repair and characterized by a stable genome. Whether genomic instability eventually occurs when PRC1 downregulation is performed for extended periods of time remains unclear. Here, we show that prolonged depletion of PH, which mimics cancer initiating events, results in broad dysregulation of DNA replication and repair genes, along with the accumulation of DNA breaks, defective repair, and widespread genomic instability in the cancer tissue. A broad misregulation of H2AK118 ubiquitylation and to a lesser extent of H3K27 trimethylation also occurs and might contribute to these phenotypes. Together, this study supports a model where DNA repair and replication defects accumulate during the tumorigenic transformation epigenetically induced by PRC1 loss, resulting in genomic instability and cancer progression.
- 18 June 2024
- Published by Springer Nature in Histochemistry and Cell Biology
- Vol. 162 (1-2) , 133-147
Open AccessSustained inactivation of the Polycomb PRC1 complex induces DNA repair defects and genomic instability in epigenetic tumors
Cancer initiation and progression are typically associated with the accumulation of driver mutations and genomic instability. However, recent studies demonstrated that cancer can also be driven purely by epigenetic alterations, without driver mutations. Specifically, a 24-h transient downregulation of polyhomeotic (ph-KD), a core component of the Polycomb complex PRC1, is sufficient to induce epigenetically initiated cancers (EICs) in Drosophila, which are proficient in DNA repair and characterized by a stable genome. Whether genomic instability eventually occurs when PRC1 downregulation is performed for extended periods of time remains unclear. Here, we show that prolonged depletion of PH, which mimics cancer initiating events, results in broad dysregulation of DNA replication and repair genes, along with the accumulation of DNA breaks, defective repair, and widespread genomic instability in the cancer tissue. A broad misregulation of H2AK118 ubiquitylation and to a lesser extent of H3K27 trimethylation also occurs and might contribute to these phenotypes. Together, this study supports a model where DNA repair and replication defects accumulate during the tumorigenic transformation epigenetically induced by PRC1 loss, resulting in genomic instability and cancer progression.
- Top Cited PapersOpen Access
- 24 April 2024
- Published by Springer Nature in Nature
- Vol. 629 (8012) , 688-696
Transient loss of Polycomb components induces an epigenetic cancer fate
Although cancer initiation and progression are generally associated with the accumulation of somatic mutations1,2, substantial epigenomic alterations underlie many aspects of tumorigenesis and cancer susceptibility3–6, suggesting that genetic mechanisms might not be the only drivers of malignant transformation7. However, whether purely non-genetic mechanisms are sufficient to initiate tumorigenesis irrespective of mutations has been unknown. Here, we show that a transient perturbation of transcriptional silencing mediated by Polycomb group proteins is sufficient to induce an irreversible switch to a cancer cell fate in Drosophila. This is linked to the irreversible derepression of genes that can drive tumorigenesis, including members of the JAK–STAT signalling pathway and zfh1, the fly homologue of the ZEB1 oncogene, whose aberrant activation is required for Polycomb perturbation-induced tumorigenesis. These data show that a reversible depletion of Polycomb proteins can induce cancer in the absence of driver mutations, suggesting that tumours can emerge through epigenetic dysregulation leading to inheritance of altered cell fates.
- 24 April 2024
- Published by Springer Nature in Nature
- Vol. 629 (8012) , 688-696
Top Cited PapersOpen AccessTransient loss of Polycomb components induces an epigenetic cancer fate
Although cancer initiation and progression are generally associated with the accumulation of somatic mutations1,2, substantial epigenomic alterations underlie many aspects of tumorigenesis and cancer susceptibility3–6, suggesting that genetic mechanisms might not be the only drivers of malignant transformation7. However, whether purely non-genetic mechanisms are sufficient to initiate tumorigenesis irrespective of mutations has been unknown. Here, we show that a transient perturbation of transcriptional silencing mediated by Polycomb group proteins is sufficient to induce an irreversible switch to a cancer cell fate in Drosophila. This is linked to the irreversible derepression of genes that can drive tumorigenesis, including members of the JAK–STAT signalling pathway and zfh1, the fly homologue of the ZEB1 oncogene, whose aberrant activation is required for Polycomb perturbation-induced tumorigenesis. These data show that a reversible depletion of Polycomb proteins can induce cancer in the absence of driver mutations, suggesting that tumours can emerge through epigenetic dysregulation leading to inheritance of altered cell fates.
- Open Access
Transient loss of Polycomb components induces an epigenetic cancer fate
Summary: Cell fate depends on genetic, epigenetic and environmental inputs that are interconnected, making it difficult to disentangle their respective contributions to cell fate decisions 1-3 , and epigenetic reprogramming is a major contributor to tumor plasticity and adaptation 4-6 . Although cancer initiation and progression are generally associated with the accumulation of somatic mutations 7,8 , substantial epigenomic alterations underlie many aspects of tumorigenesis and cancer susceptibility 9-18 , suggesting that genetic mechanisms alone may not be sufficient to drive malignant transformations 19-23 . However, whether purely non-genetic reprogramming mechanisms are sufficient to initiate tumorigenesis irrespective of mutations is unknown. Here, we show that a transient perturbation of transcriptional silencing mediated by Polycomb-Group proteins is sufficient to induce an irreversible switch to a cancer cell fate in Drosophila . This is linked to the irreversible derepression of genes that can drive tumorigenesis, including JNK and JAK-STAT signalling pathways and zfh1 , the fly homolog of the ZEB1 oncogene, which we show to be a necessary driver of the cancer fate. These data show that a reversible perturbation of Polycomb-Group protein levels can induce cancer in the absence of driver mutations and suggest that this is achieved through epigenetic inheritance of altered cell fates.
Open AccessTransient loss of Polycomb components induces an epigenetic cancer fate
Summary: Cell fate depends on genetic, epigenetic and environmental inputs that are interconnected, making it difficult to disentangle their respective contributions to cell fate decisions 1-3 , and epigenetic reprogramming is a major contributor to tumor plasticity and adaptation 4-6 . Although cancer initiation and progression are generally associated with the accumulation of somatic mutations 7,8 , substantial epigenomic alterations underlie many aspects of tumorigenesis and cancer susceptibility 9-18 , suggesting that genetic mechanisms alone may not be sufficient to drive malignant transformations 19-23 . However, whether purely non-genetic reprogramming mechanisms are sufficient to initiate tumorigenesis irrespective of mutations is unknown. Here, we show that a transient perturbation of transcriptional silencing mediated by Polycomb-Group proteins is sufficient to induce an irreversible switch to a cancer cell fate in Drosophila . This is linked to the irreversible derepression of genes that can drive tumorigenesis, including JNK and JAK-STAT signalling pathways and zfh1 , the fly homolog of the ZEB1 oncogene, which we show to be a necessary driver of the cancer fate. These data show that a reversible perturbation of Polycomb-Group protein levels can induce cancer in the absence of driver mutations and suggest that this is achieved through epigenetic inheritance of altered cell fates.
- Open Access
- 19 January 2022
- Published by Springer Nature in Cell Research
- Vol. 32 (3) , 231-253
Mechanisms of Polycomb group protein function in cancer
Cancer arises from a multitude of disorders resulting in loss of differentiation and a stem cell-like phenotype characterized by uncontrolled growth. Polycomb Group (PcG) proteins are members of multiprotein complexes that are highly conserved throughout evolution. Historically, they have been described as essential for maintaining epigenetic cellular memory by locking homeotic genes in a transcriptionally repressed state. What was initially thought to be a function restricted to a few target genes, subsequently turned out to be of much broader relevance, since the main role of PcG complexes is to ensure a dynamically choregraphed spatio-temporal regulation of their numerous target genes during development. Their ability to modify chromatin landscapes and refine the expression of master genes controlling major switches in cellular decisions under physiological conditions is often misregulated in tumors. Surprisingly, their functional implication in the initiation and progression of cancer may be either dependent on Polycomb complexes, or specific for a subunit that acts independently of other PcG members. In this review, we describe how misregulated Polycomb proteins play a pleiotropic role in cancer by altering a broad spectrum of biological processes such as the proliferation-differentiation balance, metabolism and the immune response, all of which are crucial in tumor progression. We also illustrate how interfering with PcG functions can provide a powerful strategy to counter tumor progression.
- 19 January 2022
- Published by Springer Nature in Cell Research
- Vol. 32 (3) , 231-253
Open AccessMechanisms of Polycomb group protein function in cancer
Cancer arises from a multitude of disorders resulting in loss of differentiation and a stem cell-like phenotype characterized by uncontrolled growth. Polycomb Group (PcG) proteins are members of multiprotein complexes that are highly conserved throughout evolution. Historically, they have been described as essential for maintaining epigenetic cellular memory by locking homeotic genes in a transcriptionally repressed state. What was initially thought to be a function restricted to a few target genes, subsequently turned out to be of much broader relevance, since the main role of PcG complexes is to ensure a dynamically choregraphed spatio-temporal regulation of their numerous target genes during development. Their ability to modify chromatin landscapes and refine the expression of master genes controlling major switches in cellular decisions under physiological conditions is often misregulated in tumors. Surprisingly, their functional implication in the initiation and progression of cancer may be either dependent on Polycomb complexes, or specific for a subunit that acts independently of other PcG members. In this review, we describe how misregulated Polycomb proteins play a pleiotropic role in cancer by altering a broad spectrum of biological processes such as the proliferation-differentiation balance, metabolism and the immune response, all of which are crucial in tumor progression. We also illustrate how interfering with PcG functions can provide a powerful strategy to counter tumor progression.
- Open Access
- 28 October 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (21) , 8047
Role of Polycomb Complexes in Normal and Malignant Plasma Cells
Plasma cells (PC) are the main effectors of adaptive immunity, responsible for producing antibodies to defend the body against pathogens. They are the result of a complex highly regulated cell differentiation process, taking place in several anatomical locations and involving unique genetic events. Pathologically, PC can undergo tumorigenesis and cause a group of diseases known as plasma cell dyscrasias, including multiple myeloma (MM). MM is a severe disease with poor prognosis that is characterized by the accumulation of malignant PC within the bone marrow, as well as high clinical and molecular heterogeneity. MM patients frequently develop resistance to treatment, leading to relapse. Polycomb group (PcG) proteins are epigenetic regulators involved in cell fate and carcinogenesis. The emerging roles of PcG in PC differentiation and myelomagenesis position them as potential therapeutic targets in MM. Here, we focus on the roles of PcG proteins in normal and malignant plasma cells, as well as their therapeutic implications.
- 28 October 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (21) , 8047
Open AccessRole of Polycomb Complexes in Normal and Malignant Plasma Cells
Plasma cells (PC) are the main effectors of adaptive immunity, responsible for producing antibodies to defend the body against pathogens. They are the result of a complex highly regulated cell differentiation process, taking place in several anatomical locations and involving unique genetic events. Pathologically, PC can undergo tumorigenesis and cause a group of diseases known as plasma cell dyscrasias, including multiple myeloma (MM). MM is a severe disease with poor prognosis that is characterized by the accumulation of malignant PC within the bone marrow, as well as high clinical and molecular heterogeneity. MM patients frequently develop resistance to treatment, leading to relapse. Polycomb group (PcG) proteins are epigenetic regulators involved in cell fate and carcinogenesis. The emerging roles of PcG in PC differentiation and myelomagenesis position them as potential therapeutic targets in MM. Here, we focus on the roles of PcG proteins in normal and malignant plasma cells, as well as their therapeutic implications.
- Open Access
- 10 January 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (2) , eaax4001
Widespread activation of developmental gene expression characterized by PRC1-dependent chromatin looping
Polycomb repressive complexes 1 and 2 have been historically described as transcriptional repressors, but recent reports suggest that PRC1 might also support activation, although the underlying mechanisms remain elusive. Here, we show that stage-specific PRC1 binding at a subset of active promoters and enhancers during Drosophila development coincides with the formation of three-dimensional (3D) loops, an increase in expression during development and repression in PRC1 mutants. Dissection of the dachshund locus indicates that PRC1-anchored loops are versatile architectural platforms that persist when surrounding genes are transcriptionally active and fine-tune their expression. The analysis of RING1B binding profiles and 3D contacts during neural differentiation in mice suggests that this role is conserved in mammals.
- 10 January 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (2) , eaax4001
Open AccessWidespread activation of developmental gene expression characterized by PRC1-dependent chromatin looping
Polycomb repressive complexes 1 and 2 have been historically described as transcriptional repressors, but recent reports suggest that PRC1 might also support activation, although the underlying mechanisms remain elusive. Here, we show that stage-specific PRC1 binding at a subset of active promoters and enhancers during Drosophila development coincides with the formation of three-dimensional (3D) loops, an increase in expression during development and repression in PRC1 mutants. Dissection of the dachshund locus indicates that PRC1-anchored loops are versatile architectural platforms that persist when surrounding genes are transcriptionally active and fine-tune their expression. The analysis of RING1B binding profiles and 3D contacts during neural differentiation in mice suggests that this role is conserved in mammals.